Most pages about CBD and migraine are selling something, so they skip the part where the evidence disagrees with them. This one doesn't.
The short version: for stopping an attack that has already started, the best trial to date used inhaled THC with CBD, and CBD on its own did not beat placebo at two hours. That is covered in full below.
That is one question, though, and not the only one. If THC isn't available to you — and for a lot of people it isn't — the useful question is what the CBD-only research does support, and where in a migraine pattern it might sit. Most of that is upstream of the attack: stress reactivity, sleep, and the muscle tension that often travels with both. There is human data there, with doses attached, and it is set out below.
What is Migraine?
Migraine is a neurovascular disorder characterized by recurrent attacks of moderate–severe head pain (often unilateral, throbbing) with photophobia, phonophobia, nausea/vomiting, and sometimes aura (visual or sensory disturbances). It reflects abnormal excitability in cortico-trigeminovascular pathways, with CGRP release, sterile neuroinflammation, and central sensitization driving pain and hypersensitivity. Care divides into acute (treat the attack: triptans/ditans, gepants, NSAIDs/antiemetics) and preventive therapies (CGRP mAbs/gepants, beta-blockers, topiramate, onabotulinumtoxinA, lifestyle/sleep/behavioral strategies). Against this backdrop, many people ask whether cannabidiol (CBD) can help—either to abort attacks or as prevention.
If THC isn't an option for you
The trial that produced the clearest acute result used vaporised cannabis at 6% THC with 11% CBD. If you can use that, and it is legal where you are, that is where the evidence currently points.
A lot of people can't.
Anyone in a safety-sensitive role is tested, and THC is disqualifying — commercial drivers, pilots, nurses, machine operators, anyone holding a DOT card. So is a federal contract. So is most competitive sport, under anti-doping rules that permit CBD and prohibit THC. People in recovery often rule it out on their own terms. So do parents of young children, people who may have to drive at short notice, and anyone whose work requires being sharp within the hour.
For all of them, "inhaled THC with CBD performed best" is a finding they cannot act on. That doesn't make the question go away. It changes which part of the research is relevant to them.
It is also why a 0.0% THC line exists, and why every batch is tested with the certificate published.
If oral CBD is the route you want, the Original Oil is the isolate formulation — 3000 mg of CBD in fractionated coconut oil, with no THC in it.
What the research says: Evidence for CBD & migraine
Meta-analyses & reviews
Systematic and narrative reviews conclude cannabis-based products may help some migraine outcomes, but most human signals involve THC or THC+CBD , not CBD alone; higher-quality RCTs are needed—especially for CBD-only .
A 2025 review of phytocannabinoids and migraine highlights the first RCT of vaporized cannabis for acute attacks and preclinical mechanisms (CGRP, trigeminovascular modulation), while noting CBD-only human data remain sparse .
Clinical / human trials
- Acute treatment—vaporized cannabis (double-blind, placebo-controlled, crossover RCT; N=92; 247 attacks): Four arms per patient (6% THC; 11% CBD; 6% THC + 11% CBD ; placebo). The THC+CBD combo was superior to placebo at 2 h for pain relief, pain freedom, and MBS freedom , with sustained benefits at 24–48 h and no serious AEs . CBD-dominant was not superior to placebo at 2 h (though some 1-h signals appeared), and THC-dominant improved 2-h pain relief only. | Crossover RCT · Vaporized
- Nabilone (THC analogue) reduced headache indices and analgesic intake more than ibuprofen; not CBD but relevant to overuse considerations — medication-overuse headache — nabilone vs ibuprofen. | Crossover RCT
- Reports suggest decreased attack frequency and symptom burden with cannabis use, but designs are uncontrolled and often THC-rich — observational cohorts/surveys. | Survey
Where the CBD-only evidence does apply
CBD on its own has not been shown to stop a migraine attack. It has been studied in humans, with doses reported, for several things that sit around one.
Stress reactivity. A single 600 mg oral dose lowered resting blood pressure and blunted the rise in blood pressure under stressors including mental arithmetic and the cold pressor test. Stress is among the most commonly reported migraine triggers.
Sleep. A 2023 review covering 34 studies examined CBD and sleep across a range of populations. Sleep disruption both triggers attacks and follows them.
Anxiety. A 2024 meta-analysis of 8 trials found a substantial effect for CBD against placebo in generalised anxiety, social anxiety and PTSD. Anxiety disorders are more common among people with migraine than without.
Localised muscle tension. Topical CBD has the strongest early clinical signals of any route — a controlled trial in which 250 mg topical reduced nerve pain against placebo, and small osteoarthritis trials showing improved pain and disability scores. Neck and shoulder tension frequently accompanies migraine.
None of that is migraine treatment, and we are not going to call it that. It is an honest map of where CBD-only evidence exists relative to a condition it has not been shown to treat directly.
Dose-response & dosing
Acute attacks: Evidence of benefit comes from inhaled THC+CBD (6%/11%) in the RCT above; CBD alone did not outperform placebo at 2 h . Optimal ratios, potencies, and puff counts need confirmation.
Prevention: No published CBD-only RCTs for migraine prophylaxis as of 2025. Small uncontrolled series with mixed THC/CBD oils report symptom gains but are hypothesis-generating only.
Proposed mechanisms
How might CBD intersect with migraine biology?
CGRP & trigeminovascular signaling: In nitroglycerin-based rodent models, CBD reduced trigeminal hyperalgesia, CGRP, and IL-6 in brainstem/trigeminal tissues—supporting anti-hyperalgesic, anti-inflammatory actions. BioMed Central
Neuroinflammation/oxidative stress: CBD dampens pro-inflammatory cytokines and may modulate NF-κB/NLRP3 pathways implicated in migraine sensitization (preclinical/immune data). Review context.
Receptor/ion channel targets: CBD engages 5-HT1A and TRP (e.g., TRPV1) channels, plausibly influencing nociception and pre-attack anxiety—mechanistic plausibility without definitive migraine-specific clinical proof.
Safety, tolerability, and side effects
CBD is generally well tolerated ; common effects include somnolence, fatigue, GI upset, dry mouth . High oral doses and certain combinations can raise liver enzymes .
Drug interactions: CBD can inhibit CYP3A4/CYP2C19 , potentially increasing levels of anticoagulants, antiepileptics, and other migraine-adjacent meds; review regimens before regular oral CBD use.
THC-related issues: Where THC is included (as in the effective acute RCT arm), expect euphoria, cognitive effects, and sedation —attenuated when combined with CBD vs THC alone in the RCT. Monitor for overuse and legal/safety considerations.
Limitations & uncertainties
CBD-only gap: No convincing CBD-only human evidence for acute or preventive migraine efficacy yet; the pivotal RCT found no 2-h benefit for CBD-dominant vs placebo.
Heterogeneity & bias: Many positive data come from THC-containing or uncontrolled studies with variable products/routes; placebo effects in pain/headache are substantial.
Overuse risk: Any acute treatment used too frequently can contribute to MOH ; cannabinoids are not exempt—apply standard attack-frequency limits. (Context informed by MOH literature and RCT discussion.) BioMed Central+1
What seems plausible & advisable now
Bottom line: For stopping an attack in progress, the evidence supports inhaled THC with CBD, not CBD alone. Where CBD-only evidence does exist is around the conditions that precede an attack — stress reactivity, sleep, and localised muscle tension — and in the preclinical work on CGRP and trigeminal inflammation, where CBD reduced trigeminal hyperalgesia and inflammatory markers in animal models. Larger CBD-specific trials are still needed on migraine itself.
If you are going to try it: use a third-party-tested product and read the certificate for the batch in your hand, not a generic one — ours are published here, and the Original Oil is the zero-THC oral option. Track what you are actually measuring — monthly migraine days, rescue medication use, two-hour pain relief — rather than going on impression. Review interactions if you take anything regularly, particularly with daily oral CBD. And note that overusing any acute treatment, cannabinoid or otherwise, can drive medication-overuse headache.
